# Michiel de Haan

> Michiel de Haan is a Series G investor at Aescap Venture backing Chemical and Biotechnology. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Aescap Venture](https://shizune.co/investors/profile/aescap-venture)
- Location: Laren, The Netherlands
- Total investments: 3
- Last investment: May 2014
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/michiel-de-haan-571b0261

Michiel de Haan is a Series G investor at Aescap Venture in Laren focused on Chemical and Biotechnology. Michiel de Haan is the current Founder and Managing Partner of Aescap Venture. He previously worked at Avantium as a Advisory Board and Past Chairman. Michiel de Haan attended Erasmus University Rotterdam.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Chemical | 1 | 33% |
| Biotechnology | 1 | 33% |
| Pharmaceutical | 1 | 33% |
| Renewable Energy | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series G | 1 | 33% |
| Funding Round | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Avantium | Avantium is a leading technology company specialized in advanced high-throughput R&D for applications in the energy, chemicals and pharmaceutical industries. The company's headquarters and laboratories are located in Amsterdam, in the Netherlands.Avantium's proprietary high-throughput technology enables a faster and morecost-effective development of new and improved products and production processes. Using its unique rational approach towards the design of experiments and data analysis, Avantium is capable of accomplishing innovations with superior success rate. Avantium has demonstrated the validity and commercial viability of its technology by successfully providing research services and tools to more than 70 companies worldwide, including many industry leaders. The company's mission is to increase the success rate and economics of product and process development.Building on its expertise and track record in the energy, chemicals and pharmaceutical industries, Avantium focuses on developing products in two fields:new biofuels and bio-based chemicals, and new crystal forms of marketed drugs under patent.Avantium's strategy is to progress its development programs and exploit the commercial value of its expanding patent portfolio by securing value-adding partnerships during the coming years. Avantium seeks continuous expansion of its profitable services and tools business.Avantium has assembled a team of highly educated professionals who are experts in catalysis, crystallography, organic chemistry, engineering of robotic systems, process engineering, statistics, cheminformatics and software development. Its teams collaborate closely with partner R&D organizations. | $42.1M | Series G | May 22, 2014 |  |
| Avantium | Avantium is a leading technology company specialized in advanced high-throughput R&D for applications in the energy, chemicals and pharmaceutical industries. The company's headquarters and laboratories are located in Amsterdam, in the Netherlands.Avantium's proprietary high-throughput technology enables a faster and morecost-effective development of new and improved products and production processes. Using its unique rational approach towards the design of experiments and data analysis, Avantium is capable of accomplishing innovations with superior success rate. Avantium has demonstrated the validity and commercial viability of its technology by successfully providing research services and tools to more than 70 companies worldwide, including many industry leaders. The company's mission is to increase the success rate and economics of product and process development.Building on its expertise and track record in the energy, chemicals and pharmaceutical industries, Avantium focuses on developing products in two fields:new biofuels and bio-based chemicals, and new crystal forms of marketed drugs under patent.Avantium's strategy is to progress its development programs and exploit the commercial value of its expanding patent portfolio by securing value-adding partnerships during the coming years. Avantium seeks continuous expansion of its profitable services and tools business.Avantium has assembled a team of highly educated professionals who are experts in catalysis, crystallography, organic chemistry, engineering of robotic systems, process engineering, statistics, cheminformatics and software development. Its teams collaborate closely with partner R&D organizations. | $48.2M |  | Jun 09, 2011 |  |
| Avantium | Avantium is a leading technology company specialized in advanced high-throughput R&D for applications in the energy, chemicals and pharmaceutical industries. The company's headquarters and laboratories are located in Amsterdam, in the Netherlands.Avantium's proprietary high-throughput technology enables a faster and morecost-effective development of new and improved products and production processes. Using its unique rational approach towards the design of experiments and data analysis, Avantium is capable of accomplishing innovations with superior success rate. Avantium has demonstrated the validity and commercial viability of its technology by successfully providing research services and tools to more than 70 companies worldwide, including many industry leaders. The company's mission is to increase the success rate and economics of product and process development.Building on its expertise and track record in the energy, chemicals and pharmaceutical industries, Avantium focuses on developing products in two fields:new biofuels and bio-based chemicals, and new crystal forms of marketed drugs under patent.Avantium's strategy is to progress its development programs and exploit the commercial value of its expanding patent portfolio by securing value-adding partnerships during the coming years. Avantium seeks continuous expansion of its profitable services and tools business.Avantium has assembled a team of highly educated professionals who are experts in catalysis, crystallography, organic chemistry, engineering of robotic systems, process engineering, statistics, cheminformatics and software development. Its teams collaborate closely with partner R&D organizations. | $18M |  | Oct 29, 2008 |  |

3 of 3 investments shown.

## Co-investors
- [Aster](https://shizune.co/investors/profile/aster-capital) — VC Fund, 2 deals together
- [Capricorn Partners](https://shizune.co/investors/profile/capricorn-partners) — VC Fund, 2 deals together
- [De Hoge Dennen Capital](https://shizune.co/investors/profile/de-hoge-dennen-capital) — VC Fund, 2 deals together
- [ALPLA](https://shizune.co/investors/profile/alpla) — VC Fund, 1 deal together
- [DANONE](https://shizune.co/investors/profile/danone) — VC Fund, 1 deal together
- [ING Corporate Investments](https://shizune.co/investors/profile/ing-corporate-investments) — VC Fund, 1 deal together

## About Aescap Venture

VC Fund · Amsterdam, The Netherlands

Aescap Venture is an Amsterdam-based investment company that pursues investments in biotech companies in Europe and the U.S.

4 contacts available at Aescap Venture.

| Name | Title | Profile |
| --- | --- | --- |
| Michiel de Haan | Founder and Managing Partner | https://shizune.co/investors/profile/michiel-de-haan |
| Wolfgang Noeldeke | Financial officer | https://shizune.co/investors/profile/wolfgang-noeldeke |
| Patrick Krol | managing partner | https://shizune.co/investors/profile/patrick-krol |
| Rainer Christine | Partner | https://shizune.co/investors/profile/rainer-christine |

## Similar investors

### Similar stage
- [ALSTIN Family GmbH](https://shizune.co/investors/profile/alstin-family-gmbh) — VC Fund
- [Benjamin Kahn](https://shizune.co/investors/profile/benjamin-kahn) — Angel Investor
- [GPI Capital](https://shizune.co/investors/profile/gpi-capital) — VC Fund

## FAQ

### What does Michiel de Haan invest in?

Michiel de Haan invests primarily in Chemical, Biotechnology and Pharmaceutical startups, most often at Series G and Funding Round stage. Most of the 3 investments tracked by Shizune back companies in The Netherlands. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Michiel de Haan last invest?

The most recent investment recorded for Michiel de Haan closed in May 2014. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co